Evidence map›Paper›PMID 36124923›Full record

ReviewDermatologic therapy2022

Complementary and alternative therapies in skin cancer a literature review of biologically active compounds.

Leonel Hidalgo, Cristóbal Saldías-Fuentes, Karina Carrasco, Allan C Halpern, Jun J Mao, Cristian Navarrete-Dechent

Open access · greenAbstract readReview
In one paragraph

Review in Dermatologic therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Plants (Basel, Switzerland) · 2025
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Leonel HidalgoDepartment of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0002-2782-2835
Cristóbal Saldías-FuentesDermatology Service, Hospital Dr. Carlos Cisternas de Calama, Calama, Chile.
Karina CarrascoDepartment of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Allan C HalpernDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jun J MaoIntegrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cristian Navarrete-DechentDepartment of Dermatology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.ORCID 0000-0003-4040-3640
Pontificia Universidad Católica de Chile · CLMemorial Sloan Kettering Cancer Center · USGeneral Hospital of Drama · GR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Complementary and alternative medicine or therapies (CAM) are frequently used by skin cancers patients. Patient's self-administration of CAM in melanoma can reach up to 40%-50%. CAMs such as botanical agents, phytochemicals, herbal formulas ("black salve") and cannabinoids, among others, have been described in skin cancer patients. The objective of this review article was to acknowledge the different CAM for skin cancers through the current evidence, focusing on biologically active CAM rather than mind-body approaches. We searched MEDLINE database for articles published through July 2022, regardless of study design. Of all CAMs, phytochemicals have the best in vitro evidence-supporting efficacy against skin cancer including melanoma; however, to date, none have proved efficacy on human patients. Of the phytochemicals, Curcumin is the most widely studied. Several findings support Curcumin efficacy in vitro through various molecular pathways, although most studies are in the preliminary phase. In addition, the use of alternative therapies is not exempt of risks physicians should be aware of their adverse effects, interactions with standard treatments, and possible complications arising from CAM usage. There is emerging evidence for CAM use in skin cancer, but no human clinical trials support the effectiveness of any CAM in the treatment of skin cancer to date. Nevertheless, patients worldwide frequently use CAM, and physicians should educate themselves on currently available CAMs.

Indexed as

Complementary TherapiesCurcuminMelanomaSkin NeoplasmsHumansCurcumincomplementary therapymelanomanon-melanomaskin cancerskin cancer complementary and alternative medicine

Identifiers

PMID36124923
PMCPMC10481428
OpenAlexW4297254893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.